Shanghai, November 10, 2022 –Boan Biotech today announced that self-developed Denosumab Injection (Boyoubei®) has been approved for launch in China by the National Medical Products Administratio...
October 27, 2022 -- Boan Biotech announced today that BA2101 has been approved by the Center for Drug Evaluation of the National Medical Products Administration for clinical trials in China. This is a...
Shanghai, September 12, 2022 –BA-CovMab injection, the broad-spectrum neutralizing antibody developed by Boan Biotech for use against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...
Luye Pharma Group announced on July 14 that its subsidiary Boan Biotech has started a Phase III clinical trial, which is a comparative clinical efficacy and safety study, for Dulaglutide Injection (BA...
February 25, 2022, Shanghai —Boan Biotech today announced that Boyounuo® (Bevacizumab Injection), an anticancer biologic, has been approved by China’s National Medical Products Administration (...
Luye Pharma Group today announced that the first patient has been enrolled in a Phase I clinical trial for BA1105, an investigational anti-Claudin18.2 antibody developed by its subsidiary Boan Biotech...
Shanghai, December 14, 2021—Luye Pharma Group announced that the clinical trial application for BA1201, an anti-PD-L1/TGF-β bispecific antibody developed by its subsidiary Boan Biotech, has been...
The findings about BA1106, a fully human monoclonal anti-CD25 antibody developed by Boan Biotech, a subsidiary of Luye Pharma Group, were published in Scientific Reports, which is a journal of the Nat...
Boan Biotech, a subsidiary of Luye Pharma Group, announced today that it has signed a Memorandum of Understanding with Merck, a world-leading science and technology company, under which the two partie...
Follow me
鲁公网安备37069102000284